WirthLJ, ShermanE, RobinsonB, et al.Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med, 2020; 383(9):825–835; doi: 10.1056/NEJMoa2005651
2.
ContreraKJ, Gule-MonroeMK, HuMI, et al.Neoadjuvant selective RET inhibitor for medullary thyroid cancer: A case series. Thyroid, 2023; 33(1):129–132; doi: 10.1089/thy.2022.0506
3.
CairoMS, BishopM. Tumour lysis syndrome: New therapeutic strategies and classification. Br J Haematol, 2004; 127(1):3–11; doi: 10.1111/j.1365-2141.2004.05094.x
4.
Meraz-MunozA, LangoteA, JhaveriKD, et al.Acute kidney injury in the patient with cancer. Diagnostics (Basel), 2021; 11(4):611; doi: 10.3390/diagnostics11040611
5.
GuptaS, GudsoorkarP, JhaveriKD. Acute kidney injury in critically ill patients with cancer. Clin J Am Soc Nephrol, 2022; 17(9):1385–1398; doi: 10.2215/CJN.15681221
6.
SubbiahV, HuMI, WirthLJ, et al.Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol, 2021; 9(8):491–501; doi: 10.1016/S2213-8587(21)00120-0
